Clinical trials: Human Immunodeficiency Virus I Infection
HTLV-I Infection, Tropical Spastic Paraparesis
Evaluation of Patients With HAM/TSP
Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus.
- Trial name
- NCT00001778
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Tuberculosis
A Study to Evaluate Safety and Immunogenicity of AERAS-402
This Phase I study will be conducted as a randomized, double-blind, placebo-controlled study in healthy adult subjects who are HIV-negative, BCG-vaccinated, and have no evidence of tuberculosis infection.
- Trial name
- NCT01378312
- Testing
- AERAS 402
- Where
- India
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aeras
Infection, Human Immunodeficiency Virus I, HIV Infection
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
- Trial name
- NCT00044577
- Testing
- abacavir/lamivudine, abacavir, lamivudine
- Where
- 76 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I
ZIAGEN® Post-marketing Surveillance
An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information.
- Trial name
- NCT01205243
- Testing
- ZIAGEN®
- Where
- South Korea
- Volunteers
- 671 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
To study the safety and toxicity of intranasal peptide T (D-Ala-1-peptide-T-amide) in humans, and to find out how quickly and how much of a given dose enters the bloodstream and how quickly it leaves the bloodstream.
- Trial name
- NCT00000391
- Testing
- Peptide T
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
HIV Infection
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens…
- Trial name
- NCT05208125
- Testing
- ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IrsiCaixa
HIV I Infection
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
Following the initiation of Doravirine (DOR) regimen among people living with HIV (PLWH), the study will aim to assess effectiveness, discontinuation, and resistance over the 12-month period.
- Trial name
- DrEW (NCT05421806)
- Where
- 19 sites in Belgium, France and 3 more
- Volunteers
- 500 people
- Sponsor
- NEAT ID Foundation
HIV I Infection
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
- Trial name
- DYAD (NCT04585737)
- Testing
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Charlotte-Paige Rolle, MD
Healthy, HIV Infection
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs.
- Trial name
- NCT00005673
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus I
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
This is a study in healthy adult subjects to evaluate the bioequivalence of a Combined Formulated Tablet compared with maraviroc and Combivir administered concurrently versus maraviroc + Combivir.
- Trial name
- NCT01597648
- Testing
- Maraviroc, Combivir, GSK2838510
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection
To evaluate the safety of autologous CAR-T-cell therapy in individuals lived with HIV-1 infection, CAR T cells are infused after ex vivo expansion and transduction with lentiviral vectors encoding a broadly neutralizing HIV-1…
- Trial name
- TCTIWHI (NCT04863066)
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Beijing 302 Hospital
HIV Infection
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
The purpose of this study is to compare the safety, tolerability and efficacy of a regimen containing once-daily elvitegravir (EVG) versus twice-daily raltegravir (RAL) added to a background regimen (1 fully-active ritonavir…
- Trial name
- NCT00708162
- Testing
- Elvitegravir, Raltegravir, Background regimen
- Where
- 180 sites in United States, Australia and 12 more
- Volunteers
- 724 people
- Sponsor
- Gilead Sciences
Healthy
A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
- Trial name
- MENSCH (NCT02218125)
- Testing
- MVA Mosaic
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
HIV Infections
Phase I Trial of S-1153 in Patients With HIV Infection
To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153.
- Trial name
- NCT00002214
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lexigen Pharmaceuticals
HIV Infections
A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
To determine the safety and immunogenicity of Env 2-3 in combination with MTP-PE/MF59 adjuvant in adult volunteers with HIV infection.
- Trial name
- NCT00000958
- Testing
- MTP-PE/MF59, Env 2-3
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
- Trial name
- NCT05854381
- Testing
- VIR-1388
- Where
- 10 sites in United States, South Africa
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uterine Cervical Neoplasms, HIV I Infection
Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe
The goal of this observational study is to improve cervical pre-cancer treatment outcomes among women living with HIV (WLWH), particularly in low and middle income countries (LMICs), by generating the evidence needed for…
- Conditions
- Uterine Cervical Neoplasms, HIV I Infection, HPV Infection
- Trial name
- NCT07202936
- Where
- Zimbabwe
- Volunteers
- 168 people
- Sponsor
- University of Bern
Hiv, HIV I Infection
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals.
- Trial name
- NCT06805656
- Testing
- Maraviroc, Dolutegravir, Dendritic Cell Vaccine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection
The purpose of this study is to assess the safety and effectiveness of rilpivirine hydrochloride in combination with other anti-retroviral (ARV) medications for the treatment of ARV-naive (patients who have not been exposed to…
- Trial name
- NCT01692470
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled study.
- Trial name
- NCT00000845
- Testing
- P3C541b Lipopeptide
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)